Biosimilar User Fee Agreement Includes “Financial Hold” On Development Programs For Failure To Pay

Biosimilar INDs could be placed on “financial hold” if sponsors fail to timely pay product development fees under FDA’s inaugural biosimilar user fee deal with industry.